15 completed, 5 unknown, 2 enrolling by invitation, 2 recruiting. 7 Phase 4, 6 Not applicable, 6 Phase 3, 3 Phase 1, 2 Phase 2.
Follow Esomeprazole 40mg: new trials by email Literature Review of Esomeprazole 40mg trials Research Report on Esomeprazole 40mg
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Randomized, Three-Arm Study Comparing Vonaprazan 10 mg, Vonaprazan 20 mg, and Esomeprazole 40 mg for the Healing of LA Grade B or Higher Reflux Esophagitis at 8 Weeks Vonoprazan, Esomeprazole 40mg - GERD | Not applicable | Recruiting | Asian Institute of Gastroenterology, India | 414 | 2025-12-20 | 2026-03-06 |
| Vonaprazan Versus Esomeprazole for Healing of LA Grade B or Higher Esophagitis After POEM Vonoprazan, Esomeprazole 40mg - GERD | Not applicable | Recruiting | Asian Institute of Gastroenterology, India | 300 | 2025-04-30 | 2026-04-27 |
| Comparison of the Efficacies of Two Novel Dose Dual Therapies in the First-line Helicobacter Pylori Eradication Vonoprazan, Esomeprazole 40mg, Amoxicillin - HELICOBACTER PYLORI INFECTIONS | Phase 3 | Unknown | Chang Gung Memorial Hospital | 300 | 2025-02-01 | 2025-02-12 |
| Efficacy and Safety of Tegoprazan and Minocycline Dual Therapy for Helicobacter Pylori Initial Treatment tegoprazan, Minocycline, bismuth potassium citrate - Helicobacter Pylori Infection Chronic Gastrit | Phase 4 | Active not recruiting | Xijing Hospital of Digestive Diseases | 208 | 2024-11-11 | 2025-07-03 |
| Optimal Duration of Bismuth Quadruple Therapy for Helicobacter Pylori Eradication in Females As Compared with Males Drug: Bismuth Subcitrate 120 MG Oral Tablet, Esomeprazole 40mg, Metronidazole 250 MG - Helicobacter Pylori Infection, Sex | Phase 4 | Enrolling by invitation | National Cheng-Kung University Hospital | 661 | 2024-07-09 | 2024-11-07 |
| Efficacy and Safety of a Triple Eradication Scheme for Helicobacter Pylori Based on Tegoprazan vs Esomeprazole Tegoprazan, Esomeprazole 40mg - Helicobacter Pylori Infection | Phase 4 | Unknown | Hospital General de México Dr. Eduardo Liceaga | 160 | 2024-04-19 | 2024-03-19 |
| JP-1366 20mg Versus Esomeprazole 40mg in Patients With Erosive Esophagitis JP-1366 20mg, Esomeprazole 40mg - Erosive Esophagitis | Phase 3 | Completed | Onconic Therapeutics Inc. | 300 | 2022-01-17 | 2024-08-27 |
| A Multi-center, Double-blinding, Parallel and Positive-controlled Phase III Clinical Trial for Efficacy and Safety Evaluation of Ilaprazole Sodium for Injection on Prevention of Stress Ulcer Bleeding Esomeprazole 40mg, Ilaprazole Sodium, Placebo 1 - Stress Ulcer Bleeding | Phase 3 | Completed | Livzon Pharmaceutical Group Inc. | 449 | 2021-07-16 | 2023-05-03 |
| Comparison Between High-dose Amoxicillin Dual Therapy and Pylera Quadruple Therapy in the Treatment of Helicobacter Pylori Infection Amoxicillin - high dose dual therapy, Pylera, Esomeprazole 40mg - Helicobacter Pylori Infection, Gastritis | Early Phase 1 | Unknown | Unidade Local de Saúde do Alto Ave, EPE | 100 | 2021-05-01 | 2021-10-29 |
| The Efficacy of 10-day and 14-day Bismuth-based Quadruple Therapy in First-line H. Pylori Eradication Bismuth Subcitrate 120 MG Oral Tablet, Lactobacillus acidophilus and Bifidobacterium lactis Bb12, Esomeprazole 40mg - Helicobacter Pylori Infection, Dysbiosis | Phase 4 | Enrolling by invitation | National Cheng-Kung University Hospital | 312 | 2020-05-06 | 2024-06-24 |
| Clinical Trial to Evaluate the Safety and Efficacy of JP-1366 in Patients With Erosive Gastroesophageal Reflux Disease JP-1366, JP-1366 placebo, Esomeprazole 40mg - GERD | Phase 2 | Completed | Onconic Therapeutics Inc. | 188 | 2019-11-15 | 2022-07-13 |
| Genotypic Resistance-guided Versus Empirical Therapy for H. Pylori Eradication. Esomeprazole 40mg, Clarithromycin 500mg, Metronidazole 500 mg - Helicobacter Pylori Infection | Phase 4 | Unknown | Konstantopoulio-Patission General Hospital of Nea Ionia | 304 | 2019-09-01 | 2019-09-19 |
| A Study to Compare PK, PD and Safety of the AD-206 and Esomeprazole AD-206 20mg, Esomeprazole 20mg, AD-206 40mg - Gastritis | Phase 1 | Completed | Addpharma Inc. | 88 | 2019-06-05 | 2021-01-13 |
| Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Erosive Gastroesophageal Reflux Disease (Phase 3) DWP14012 40mg, DWP14012 40mg placebo, Esomeprazole 40mg - Erosive Esophagitis | Phase 3 | Completed | Daewoong Pharmaceutical Co. LTD. | 263 | 2018-12-13 | 2020-09-03 |
| Efficacy and Safety of LXI-15028 Comparing With Esomeprazole in the Treatment of Erosive Esophagitis LXI-15028 50mg, Esomeprazole 40mg - Erosive Esophagitis (EE) | Phase 3 | Completed | Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. | 261 | 2018-10-24 | 2020-04-15 |
| Genotypic Resistance Guided Therapy for Refractory H. Pylori Infection Esomeprazole 40mg, Amoxicillin, metronidazole - H Pylori Infection | Phase 4 | Unknown | National Taiwan University Hospital | 320 | 2017-12-15 | 2018-06-13 |
| Study to Confirm the Safety and Efficacy of CJ-12420 in Patients With Erosive Esophagitis CJ-12420 100mg QD, Esomeprazole 40mg, CJ-12420 50mg QD - Erosive Esophagitis | Phase 3 | Completed | HK inno.N Corporation | 302 | 2016-05-02 | 2017-09-12 |
| The Effect of Esomeprazole on Type 2 Diabetes Esomeprazole 40mg - Diabetes Mellitus, Type 2 | Not applicable | Completed | Baskent University Ankara Hospital | 32 | 2015-12-01 | 2018-07-26 |
| Levofloxacin Triple and Bismuth Quadruple Therapies for Rescue Treatment of H Pylori Infection esomeprazole+amox+levo, esomeprazole+bismuth+tetra+levo - Helicobacter Pylori Infection | Not applicable | Completed | Kaohsiung Veterans General Hospital. | 102 | 2015-02-01 | 2019-03-14 |
| Comparison of Two Rescue Therapies for Helicobacter Pylori Infection esomeprazole+amox+levo+tetra, esomeprazole+amox+levo - Helicobacter Pylori Infection | Not applicable | Completed | Kaohsiung Veterans General Hospital. | 51 | 2013-11-01 | 2019-03-14 |
Showing 20 of 25. Sign in to see all of them.
Gastroesophageal Reflux (5) · Gastritis (2) · Barrett Esophagus (1) · Coitus (1) · Diabetes Mellitus, Type 2 (1) · Dysbiosis (1) · Esophagitis, Peptic (1) · Heartburn (1) · Stomach Neoplasms (1)
Kaohsiung Veterans General Hospital. (3) · Asian Institute of Gastroenterology, India (2) · HK inno.N Corporation (2) · National Cheng-Kung University Hospital (2) · Onconic Therapeutics Inc. (2) · Yuhan Corporation (2) · Addpharma Inc. (1) · AstraZeneca (1) · Baskent University Ankara Hospital (1) · Chang Gung Memorial Hospital (1) · Daewoong Pharmaceutical Co. LTD. (1) · Hospital General de México Dr. Eduardo Liceaga (1) · Konstantopoulio-Patission General Hospital of Nea Ionia (1) · Livzon Pharmaceutical Group Inc. (1) · National Taiwan University Hospital (1)
South Korea (8) · Taiwan (6) · China (3) · India (2) · Greece (1) · Portugal (1) · Puerto Rico (1) · United States (1)
Mohan Dr Ramchandani, MD DM (2) · Hsiu-Chi Cheng, MD, PhD (1) · Hsiu-Chi Cheng, PhD (1) · In-Jin Jang, M.D.,Ph.D (1) · Jyh-Ming Liou, MD, PhD (1) · Kathryn Collison (1) · Kyun-Seop Bae, MD, Ph.D (1) · Kyung-Sang Yu, MD, PhD (1) · Marta Illueca, MD (1) · Myung Gyy Choi, M.D., Ph.D. (1) · Ping-I Hsu (1)
PMID 20456300, PMID 36463082, PMID 37178702, PMID 38500841, PMID 38976448, PMID 39474720, PMID 40984972